Celladon Corporation (NASDAQ:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, announced that its lead product candidate, MYDICAR(R), has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative. Celladon Corp (NASDAQ:CLDN) shares after opening at $12.50 moved to $13.40 on last trade day and at the end of the day closed at $11.87. Company price to sales ratio in past twelve months was calculated as – and price to cash ratio as 9.42. Celladon Corp (NASDAQ:CLDN) showed a positive weekly performance of 22.37%.
SIGA Technologies, Inc. (NASDAQ:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, on 10 march reported its financial results for the quarter and year ended December 31, 2013. SIGA Technologies, Inc. (NASDAQ:SIGA) shares advanced 0.33% in last trading session and ended the day on $3.00. SIGA return on equity ratio is recorded as -103.30% and its return on assets is -12.60%. SIGA Technologies, Inc. (NASDAQ:SIGA) yearly performance is -10.18%.
Ambit Biosciences Corporation (NASDAQ:AMBI) announced that it has commenced a phase III study (QUANTUM-R) on its lead oncology candidate, quizartinib. Quizartinib is a once-daily, orally administered FMS-like tyrosine kinase-3 (FLT3) inhibitor. Ambit Biosciences Corp (NASDAQ:AMBI) shares moved down -6.86% in last trading session and was closed at $8.15, while trading in range of $8.05 – $8.75. Ambit Biosciences Corp (NASDAQ:AMBI) year to date (YTD) performance is -15.46%.
Evogene Ltd. (NYSE:EVGN) a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, on 8 April announced that it has filed its annual report containing audited consolidated financial statements for the year ended December 31, 2013 with the United States Securities and Exchange Commission, on Form 20-F. Evogene Ltd (NYSE:EVGN) weekly performance is -5.45%. On last trading day company shares ended up $18.20. Evogene Ltd (NYSE:EVGN) distance from 50-day simple moving average (SMA50) is -3.91%. Analysts mean target price for the company is $23.75.